In summary, we found that not only pediatric AML, which consistently express CD33 on the cell surface but also CD33+ ALL, characterized by inferior prognosis, are potential targets for CD16xCD33 BiKE. This evidence concerns the gene CD33 and acute myeloid leukemia.